A common feature of these five studies is that all were conducted outside the currently approved indications and all were performed in predominantly mild or nonanaemic patients, with target Hb levels higher than those recommended by the EORTC guidelines (Bokemeyer et al, 2007), for the use of ESA therapy in cancer patients treated with chemotherapy. This evidence concerns the gene GSTM1 and cancer.